literature

HIV mutation literature information.

DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).

PMID: 35336931 2022 Viruses

Abstract: DT started within 7 days of first specialist consultation in all patients and the same day in 84.1%; 3.4% had baseline resistance mutations (K103N, V106I + E138A, and V108I); 12.5% were lost to follow-up.

Result: Baseline resistance mutations (K103N, V106I + E138A, and V108I, respectively) were detected in three patients (3.4%).

Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week.

PMID: 34654041 2022 Journal of acquired immune deficiency syndromes (1999)

Method: Inclusion criteria included diagnosis of HIV-1 infection >=3 months before screening, plasma HIV-1 RNA >=10,000 copies/mL, CD4+ T-cell count >200/mm3, no evidence of NNRTI-associated resistance mutations (eg, K103N, Y181C, and V108I) appearing in the Stanford University HIV Drug Resistance Database, and no evidence of active hepatitis C or hepatitis B infection.

Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.

PMID: 34871089 2022 Antimicrobial agents and chemotherapy

Method: Patients with previously documented HIV-2 infection, with active AIDS, and with documented genotypic evidence of >=1 NNRTI resistance-associated mutation (RAM) from a predefined list of the following NNRTI RAMs at screening were excluded: A98G, L100I, K101E, K101P, K101Q, K103H, K103N, K103S, K103T, V106A, V106M, V108I, E138A, E138G,

Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes.

PMID: 34873084 2022 AIDS (London, England)

Table: V108V/I

Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.

PMID: 34897227 2022 Journal of acquired immune deficiency syndromes (1999)

Table: V108I

Prevalence of HIV-1 drug resistance in Eastern European and Central Asian countries.

PMID: 35061671 2022 PloS one

Table: V108I

Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand.

PMID: 35001501 2022 Journal of the International AIDS Society

Method: We excluded individuals with prior evidence of NNRTI-associated resistance mutations based on the IAS-USA HIV drug-resistance mutations list (2019) (V90I, A98G, L100I, K101E/H/P/Q/R/N, K103N/S, V106A/M/I, V108I, E138K/A/G/Q/R, V179D/F/L/T, Y181C/I/V, Y188L/C/H, G190A/S/E,H221Y, P225H, F227L/C/R,

HIV-1-infection in a man who has sex with men despite self-reported excellent adherence to pre-exposure prophylaxis, the Netherlands, August 2021: be alert to emtricitabine/tenofovir-resistant strain transmission.

PMID: 35393931 2022 Euro surveillance

Abstract: Sequencing identified resistance-associated mutations (RAM) M184V and K65R, conferring resistance to emtricitabine and tenofovir, and RAM V108I and E138A.

Discussion: A combination of RAM similar to those found in this case (M184V, K65R, V108I and E138A) has not been reported in PrEP users.

Discussion: Possible explanations for the PrEP failure in our case include: (i) HIV infection by transmission of a strain with several RAM (M184V, K65R, V108I and E138A); (ii) HIV i

Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania.

PMID: 35107140 2022 The Journal of antimicrobial chemotherapy

Table: V108I

HIV-1 Drug Resistance and Genetic Transmission Networks Among MSM Failing Antiretroviral Therapy in South China 2014-2019.

PMID: 34377002 2021 Infection and drug resistance

Table: V108I

Browser Board

Co-occurred Entities

Filtrator